secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zentalis Pharmaceuticals, Inc. (ZNTL)
CIK:        0001725160
Form:       8-K
Filed at:   2022-11-09T23:59:59+00:00
Accession:  0001725160-22-000199
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zentalis Q3 cash $421.7M, ZN-c3 dose optimization extends USC trial; Cyclin E biomarker strategy set
--------------------------------------------------------------------------------

- Cash $421.7M as of Sep 30, 2022; runway into Q1 2025.
- R&D expenses $42.2M (down 22% YoY); G&A $12.0M (up 35% YoY).
- ZN-c3 dose optimization extends USC trial timeline; update expected H1 2023.
- Cyclin E amplification/overexpression selected as biomarker for ZN-c3 monotherapy in ovarian cancer.
- Appointed new CMO (Carrie Brownstein), CSO (Kevin Bunker), CTO (Mark Lackner); added board member Jan Skvarka.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1725160/000172516022000199/0001725160-22-000199-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1725160/000172516022000199/zntl-20221109.htm
  HTML page:      https://secwatch.observer/filing/0001725160-22-000199

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer